TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes
暂无分享,去创建一个
H. Votavova | D. Mikulenková | Z. Zemanová | J. Březinová | K. Michalová | J. Čermák | M. Merkerova | M. Belickova | J. Valka | A. Jonasova | R. Neuwirtová | J. Vesela | M. Lauermannova | Barbora Pejsova | A. Jonášová | M. Merkerová
[1] G. Garcia-Manero. Myelodysplastic syndromes: 2015 Update on diagnosis, risk‐stratification and management , 2015, American journal of hematology.
[2] D. Birnbaum,et al. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes , 2015, Oncotarget.
[3] Christopher A. Miller,et al. The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML , 2014, Nature.
[4] D. Neuberg,et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] C. Preudhomme,et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. , 2014, Leukemia research.
[6] Torsten Haferlach,et al. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome , 2014, Genes, chromosomes & cancer.
[7] Raul Rabadan,et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. , 2013, Blood.
[8] M. Cazzola,et al. The genetic basis of myelodysplasia and its clinical relevance. , 2013, Blood.
[9] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[10] P. Fenaux,et al. How we treat lower-risk myelodysplastic syndromes. , 2013, Blood.
[11] G. Mufti,et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis , 2013, British journal of haematology.
[12] A. McKenna,et al. Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.
[13] Carsten Denkert,et al. Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization , 2012, PloS one.
[14] A. Stamatoullas,et al. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion , 2012, Genes, chromosomes & cancer.
[15] D. Neuberg,et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[17] Z. Zemanová,et al. Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q- MDS (IPSS low and intermediate-1). , 2011, Leukemia research.
[18] Eva Hellström-Lindberg,et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Varda Rotter,et al. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. , 2011, Genes & cancer.
[20] M. Mittelman,et al. The lower risk MDS patient at risk of rapid progression. , 2010, Leukemia research.
[21] M. Lübbert,et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] P. Nguyen,et al. Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.
[23] H. Kantarjian,et al. A prognostic score for patients with lower risk myelodysplastic syndrome , 2008, Leukemia.
[24] H. Deeg,et al. Hematologic malignancies : myelodysplastic syndromes , 2006 .
[25] Luca Malcovati,et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[27] Iscn. International System for Human Cytogenetic Nomenclature , 1978 .